AMPrEP in H-TEAM: A PrEP implementation project in Amsterdam

Prof. dr. Maria Prins

Public Health Service (GGD) and Academic Medical Centre, Amsterdam, The Netherlands




Joining forces for a future with no new HIV infections

Joining forces for a future with no new HIV infections




Amsterdam Continuum of Prevention and Care





Pre-start research at the city level





Janneke P. Bil^a, Udi Davidovich^a, Wendy M. van der Veldt^a, Maria Prins^{a,b}, Henry J.C. de Vries^{b,c,d}, Gerand and L

Observational Study



Motives of Dutch men who have sex with men for daily and intermittent HIV pre-exposure prophylaxis usage and preferences for implementation

A qualitative study

Janneke P. Bil, MSca,*, Wendy M. van der Veldt, MSca, Maria Prins, PhDa, Ineke G. Stolte, PhDa, Udi Davidovich, PhDa*

Although PrEP is not yet registered in Europe, including the Netherlands, its approval and implementation are expected in the near future. To inform future pre-exposure prophylaxis (PrEP) implementation, this study aimed to gain insight into motives and

preferences for daily or intermittent PrEP use among Dutch HIV-negative men having sex with men (MSM). Between February and December 2013, semistructured interviews were conducted until data saturation was reached (N=20).

ary and December 2015, serial determinants

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.

AIDS 2015, 29:955-964

C be tha

Amsterdam PrEP (AMPrEP) demonstration project

PrEP is being offered

- to 370 MSM and transgender people
- as part of an integrated prevention package
- at a large and free-of charge STI clinic
- August 2015 June 2018

App to facilitate adherence and monitor safe sex

Choice: daily or event-driven PrEP

Outcomes	uptake, acceptability, and usability of PrEP
	adherence, risk behaviour, STI and HIV, cost- effectiveness





AMPrEP Results

June 2015: 350 online applications within 24 hours

Project cannot accommodate the larger population in need of PrEP

August 2015-August 2016: 376 individuals started PrEP

Majority (73%) chose daily PrEP

Baseline characteristics

- Bacterial STI: 21%
- HCV RNA prevalence (4%) higher than expected. HCV infections are more closely monitored during PrEP follow-up
- Daily PrEP users were younger, reported more often multiple risk factors for HIV infection and more anal sex partners (15 vs. 10 in past 3 months)



Acknowledgements AMPrEP

Team Research and STI clinic

GGD Amsterdam

Maria Prins en Henry de Vries (PI)

Roel Achterbergh, Kees de Jong, Ilya Peters,

Princella Felippe

Maarten Schim van der Loeff, Udi Davidovich

Jannie van der Helm, Yvonne van Duijnhoven

Arjan Hogewoning, Gerard Sonder

Alfons Hendriks, Lia Peters, Anne-wiek Ferweda

Dieke Martini, Titia Heijman, Adriaan Tempert

Menne Bartelsman en Jeroen Laverge

Kim Visser en Roelien Prins

Gerben Rienk en Linda May

Sanne van Meeteren

ZonMW grant nr 522002003

AIDS fonds, grant nr 2013169



All participants of AMPrEP

All H-team colleagues
All H-team sponsors



Laboratory

Paul Oostvogel
Sylvia Bruisten
Ineke Linde
Karin Adams
Dewi Usmany
Homeyra Amir
Khosravi Agchay
Alle analisten

Sanquin Thijs van de Laar

RIVM Ardine de Wit Maria Xiridou Silke David